{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:16:36Z","timestamp":1787066196806,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,8,18]],"date-time":"2012-08-18T00:00:00Z","timestamp":1345248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2415-12-42","type":"journal-article","created":{"date-parts":[[2012,8,18]],"date-time":"2012-08-18T04:13:58Z","timestamp":1345263238000},"source":"Crossref","is-referenced-by-count":43,"title":["Cyclosporine a 0.05% eye drops for the treatment of subepithelial infiltrates after epidemic keratoconjunctivitis"],"prefix":"10.1186","volume":"12","author":[{"given":"Seydi","family":"Okumus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erol","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Gurkan","family":"Tatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdal","family":"Kaydu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Yayuspayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Comez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Erbagci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Gurler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,8,18]]},"reference":[{"key":"274_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0161-6420(02)00992-2","volume":"109","author":"J Hillenkamp","year":"2002","unstructured":"Hillenkamp J, Reinhard T, Ross RS, B\u00f6hringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehart E, Sundmacher R: The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology. 2002, 109: 845-850. 10.1016\/S0161-6420(02)00992-2.","journal-title":"Ophthalmology"},{"key":"274_CR2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1001\/archopht.116.7.900","volume":"116","author":"YJMD Gordon","year":"1998","unstructured":"Gordon YJMD, Araullo-Cruz TP, Romanowski EGMS: The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication. Arch Ophthalmol. 1998, 116: 900-905.","journal-title":"Arch Ophthalmol"},{"key":"274_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1001\/archopht.119.10.1487","volume":"119","author":"J Hillenkamp","year":"2001","unstructured":"Hillenkamp J, Reinhard T, Ross RS, B\u00f6hringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehart E, Sundmacher R: Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study. Arch Ophthalmol. 2001, 119: 1487-1491. 10.1001\/archopht.119.10.1487.","journal-title":"Arch Ophthalmol"},{"key":"274_CR4","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1001\/archopht.1978.03910060465016","volume":"96","author":"OE Lund","year":"1978","unstructured":"Lund OE, Stefani FH: Corneal histology after epidemic keratoconjunctivitis. Arch Ophthalmol. 1978, 96: 2085-2088. 10.1001\/archopht.1978.03910060465016.","journal-title":"Arch Ophthalmol"},{"key":"274_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/ICO.0b013e318033bd25","volume":"27","author":"A Sahin","year":"2008","unstructured":"Sahin A, Bozkurt B, Irkec M: Topical cyclosporine a in the treatment of superior limbic keratoconjunctivitis: a long-term follow-up. Cornea. 2008, 27: 193-195. 10.1097\/ICO.0b013e318033bd25.","journal-title":"Cornea"},{"key":"274_CR6","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1097\/ICO.0b013e31812dfab3","volume":"26","author":"AA Ozcan","year":"2007","unstructured":"Ozcan AA, Ersoz TR, Dulger E: Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea. 2007, 26: 1035-1038. 10.1097\/ICO.0b013e31812dfab3.","journal-title":"Cornea"},{"key":"274_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0181-5512(07)91357-1","volume":"30","author":"S Doan","year":"2007","unstructured":"Doan S, Gabison E, Abitbol O, Gatinel D, Chast F, Hoang-Xuan T: Efficacy of topical 2% cyclosporine A as a steroid-sparing agent in steroid-dependent vernal keratoconjunctivitis. J Fr Ophtalmol. 2007, 30: 697-701. 10.1016\/S0181-5512(07)91357-1.","journal-title":"J Fr Ophtalmol"},{"key":"274_CR8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/ICO.0b013e3181c33034","volume":"29","author":"E Levinger","year":"2010","unstructured":"Levinger E, Slomovic A, Sansanayudh W, Bahar I, Slomovic AR: Topical treatment with 1% cyclosporine for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis. Cornea. 2010, 29: 638-640.","journal-title":"Cornea"},{"key":"274_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/ICO.0b013e31820cd607","volume":"30","author":"BH Jeng","year":"2011","unstructured":"Jeng BH, Holsclaw DS: Subepithelial Infiltrates After Adenoviral Keratoconjunctivitis. Cornea. 2011, 30: 958-961. 10.1097\/ICO.0b013e31820cd607.","journal-title":"Cornea"},{"key":"274_CR10","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s003470070025","volume":"97","author":"T Reinhard","year":"2000","unstructured":"Reinhard T, Godehardt E, Pfahl HG, Sundmacher R: Local cyclosporin A in nummuli after keratoconjunctivitis epidemica. A pilot study. Ophthalmologe. 2000, 97: 764-768. 10.1007\/s003470070025.","journal-title":"Ophthalmologe"},{"key":"274_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/01.ico.0000127481.23714.b6","volume":"24","author":"EG Romanowski","year":"2005","unstructured":"Romanowski EG, Pless P, Yates KA, Gordon YJ: Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea. 2005, 24: 86-91. 10.1097\/01.ico.0000127481.23714.b6.","journal-title":"Cornea"},{"key":"274_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/00003226-199305000-00006","volume":"12","author":"JB Ward","year":"1993","unstructured":"Ward JB, Siojo LG, Waller SG: A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis. Cornea. 1993, 12: 216-221. 10.1097\/00003226-199305000-00006.","journal-title":"Cornea"},{"key":"274_CR13","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3181\/00379727-127-32862","volume":"127","author":"JM Little","year":"1968","unstructured":"Little JM, Lorenzetti DW, Brown DC, Schweem HH, Jones BR, Kaufman HE: Studies of adenovirus type 3 infection treated with methisazone and trifluorothymidine. Proc Soc Exp Biol Med. 1968, 127: 1028-1032.","journal-title":"Proc Soc Exp Biol Med"},{"key":"274_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1055\/s-2008-1046272","volume":"197","author":"H Hutter","year":"1990","unstructured":"Hutter H: Epidemic keratoconjunctivitis: treatment results during an epidemic. Klin Monbl Augenheilkd. 1990, 197: 214-217. 10.1055\/s-2008-1046272.","journal-title":"Klin Monbl Augenheilkd"},{"key":"274_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0039-6257(86)90035-4","volume":"31","author":"RB Nussenblatt","year":"1986","unstructured":"Nussenblatt RB, Palestine AG: Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol. 1986, 31: 159-169. 10.1016\/0039-6257(86)90035-4.","journal-title":"Surv Ophthalmol"},{"key":"274_CR16","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3129\/i06-061","volume":"41","author":"A Kilic","year":"2006","unstructured":"Kilic A, Gurler B: Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol. 2006, 41: 693-698. 10.3129\/I06-061.","journal-title":"Can J Ophthalmol"},{"key":"274_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0002-9394(14)70704-4","volume":"109","author":"JT Liegner","year":"1990","unstructured":"Liegner JT, Yee RW, Wild JH: Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990, 109: 610-612.","journal-title":"Am J Ophthalmol"},{"key":"274_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s004170050204","volume":"237","author":"T Reinhard","year":"1999","unstructured":"Reinhard T, Sundmacher R: Topical cyclosporin A in Thygeson\u2019s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol. 1999, 237: 109-112. 10.1007\/s004170050204.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"274_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/00003226-199309000-00008","volume":"12","author":"EJ Holland","year":"1993","unstructured":"Holland EJ, Olsen TW, Ketcham JM, Florine C, Krachmer JH, Purcell JJ, Lam S, Tessler HH, Sugar J: Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 1993, 12: 413-419. 10.1097\/00003226-199309000-00008.","journal-title":"Cornea"},{"key":"274_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/01.ICL.0000062460.03555.32","volume":"29","author":"CB Cosar","year":"2003","unstructured":"Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ: Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens. 2003, 29: 103-107. 10.1097\/01.ICL.0000062460.03555.32.","journal-title":"Eye Contact Lens"},{"key":"274_CR21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3928\/0191-3913-19790901-07","volume":"16","author":"YJ Gordon","year":"1979","unstructured":"Gordon YJ, Mokete M: Penetrating keratoplasty in children. J Pediatr Ophthalmol Strabismus. 1979, 16: 297-300.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"274_CR22","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/S0161-6420(03)00538-4","volume":"110","author":"HD Perry","year":"2003","unstructured":"Perry HD, Doshi-Carnevale S, Donnenfeld ED, Kornstein HS: Topical cyclosporine A 0.5% as a possible new treatment for superior limbic keratoconjunctivitis. Ophthalmology. 2003, 110: 1578-1581. 10.1016\/S0161-6420(03)00538-4.","journal-title":"Ophthalmology"},{"key":"274_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.bmt.1701304","volume":"22","author":"E Kiang","year":"1998","unstructured":"Kiang E, Tesavibul N, Yee R, Kellaway J, Przepiorka D: The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant. 1998, 22: 147-151. 10.1038\/sj.bmt.1701304.","journal-title":"Bone Marrow Transplant"},{"key":"274_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/00003226-200203000-00006","volume":"21","author":"HD Perry","year":"2002","unstructured":"Perry HD, Doshi SJ, Donnenfeld ED, Bai GS: Topical cyclosporine A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea. 2002, 21: 161-163. 10.1097\/00003226-200203000-00006.","journal-title":"Cornea"},{"key":"274_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1159\/000027538","volume":"214","author":"M Shimura","year":"2000","unstructured":"Shimura M, Yasuda K, Fuse N, Nakazawa M, Tamai M: Effective treatment with topical cyclosporin A of a patient with Cogan syndrome. Ophthalmologica. 2000, 214: 429-432. 10.1159\/000027538.","journal-title":"Ophthalmologica"},{"key":"274_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0021-5155(99)00025-8","volume":"43","author":"Y Fujino","year":"1999","unstructured":"Fujino Y, Joko S, Masuda K, Yagi I, Koqure M: Sakai J, Usui M, Kotake S, Matsuda H, Ikeda E, Mochizuki M, Nakamura S, Ohno S: Ciclosporin microemulsion preconcentrate treatment of patients with Behcet\u2019s disease. Jpn J Ophthalmol. 1999, 43: 318-326. 10.1016\/S0021-5155(99)00025-8.","journal-title":"Jpn J Ophthalmol"},{"key":"274_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000268041","volume":"29","author":"K Gunduz","year":"1997","unstructured":"Gunduz K, Ozdemir O: Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 1997, 29: 405-408. 10.1159\/000268041.","journal-title":"Ophthalmic Res"},{"key":"274_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s004170050257","volume":"237","author":"A Heiligenhaus","year":"1999","unstructured":"Heiligenhaus A, Steuhl KP: Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999, 237: 435-438. 10.1007\/s004170050257.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"274_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/00003226-199311000-00004","volume":"12","author":"JC Zhao","year":"1993","unstructured":"Zhao JC, Jin XY: Immunological analysis and treatment of Mooren\u2019s ulcer with cyclosporin A applied topically. Cornea. 1993, 12: 481-488. 10.1097\/00003226-199311000-00004.","journal-title":"Cornea"},{"key":"274_CR30","first-page":"392","volume":"40","author":"M Hingorani","year":"1999","unstructured":"Hingorani M, Calder VL, Buckley RJ, Lightman S: The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Invest Ophthalmol Vis Sci. 1999, 40: 392-399.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"274_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3109\/02713683.2010.490320","volume":"35","author":"C G\u00fcrdal","year":"2010","unstructured":"G\u00fcrdal C, Gen\u00e7 I, Sara\u00e7 O, G\u00f6n\u00fcl I, Takmaz T, Can I: Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression. Curr Eye Res. 2010, 35: 771-777. 10.3109\/02713683.2010.490320.","journal-title":"Curr Eye Res"},{"key":"274_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","volume":"147","author":"EC Kim","year":"2009","unstructured":"Kim EC, Choi JS, Joo CK: A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009, 147: 206-213. 10.1016\/j.ajo.2008.08.015.","journal-title":"Am J Ophthalmol"},{"key":"274_CR33","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2147\/OPTH.S19469","volume":"5","author":"E Turan-Vural","year":"2011","unstructured":"Turan-Vural E, Torun-Acar B, Kivanc SA, Acar S: The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery. Clin Ophthalmol. 2011, 5: 881-885.","journal-title":"Clin Ophthalmol"},{"key":"274_CR34","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1097\/ICO.0b013e3181e456f0","volume":"29","author":"JB Malta","year":"2010","unstructured":"Malta JB, Soong HK, Shtein RM, Musch DC, Rhoades W, Sugar A, Mian SI: Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea. 2010, 29: 1392-1396. 10.1097\/ICO.0b013e3181e456f0.","journal-title":"Cornea"},{"key":"274_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/01.ico.0000176611.88579.0a","volume":"25","author":"HD Perry","year":"2006","unstructured":"Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH: Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006, 25: 171-175. 10.1097\/01.ico.0000176611.88579.0a.","journal-title":"Cornea"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2415-12-42\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-42","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-12-42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T15:55:51Z","timestamp":1643212551000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/1471-2415-12-42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,18]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["274"],"URL":"https:\/\/doi.org\/10.1186\/1471-2415-12-42","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,18]]},"article-number":"42"}}